---
created: '2026-02-13T18:51:24.653479Z'
description: A genetically determined, highly atherogenic lipoprotein consisting of
  an LDL-like particle bound to apolipoprotein(a). Independent risk factor for cardiovascular
  disease.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/biomarker/lpa/
slug: lpa
tags:
- biomarker
templateEngineOverride: njk
title: Lp(a)
type: biomarker
updated: '2026-02-13T18:51:24.653479Z'
---

{% raw %}
<h1>Lp A</h1>
<h2>Overview</h2>
<p><strong>Lipoprotein(a)</strong>, or <strong>Lp(a)</strong>, is a unique lipoprotein particle. It is essentially an LDL (&quot;bad cholesterol&quot;) particle that has a second protein, <strong>apolipoprotein(a)</strong> or apo(a), attached to it via a disulfide bridge.</p>
<p>Unlike LDL cholesterol, Lp(a) levels are determined almost entirely (&gt;90%) by genetics (specifically the <em>LPA</em> gene) and are not significantly influenced by diet or lifestyle.</p>
<h2>Pathophysiology</h2>
<p>Lp(a) is a &quot;triple threat&quot; for cardiovascular disease:</p>
<ol>
<li><strong>Atherogenic:</strong> Like LDL, it can penetrate arterial walls and deposit cholesterol, forming plaque.</li>
<li><strong>Pro-thrombotic:</strong> The apo(a) protein is structurally similar to plasminogen but lacks enzymatic activity. It competes with plasminogen for binding sites, inhibiting clot breakdown (fibrinolysis) and promoting clot formation.</li>
<li><strong>Pro-inflammatory:</strong> It carries oxidized phospholipids (OxPL), which trigger inflammation in blood vessel walls.</li>
</ol>
<h2>Clinical Significance</h2>
<ul>
<li><strong>Independent Risk Factor:</strong> Elevated Lp(a) is a causal risk factor for myocardial infarction (heart attack), ischemic stroke, and aortic valve stenosis.</li>
<li><strong>Residual Risk:</strong> Explains why some people have heart attacks despite having normal LDL cholesterol.</li>
<li><strong>Testing:</strong> Recommendations are shifting towards testing Lp(a) at least once in every adult's lifetime.</li>
</ul>
<h2>Management</h2>
<p>Lp(a) is notoriously difficult to lower.</p>
<ul>
<li><strong>Statins:</strong> Do NOT lower Lp(a) and may slightly increase it.</li>
<li><strong>PCSK9 Inhibitors:</strong> Can reduce Lp(a) by 20-30%.</li>
<li><strong>Niacin:</strong> Lowers levels but did not show clinical benefit in trials.</li>
<li><strong>Emerging Therapies:</strong> Antisense oligonucleotides (e.g., Pelacarsen) and siRNAs (e.g., Olpasiran) in clinical trials show potent reductions &gt;80%.</li>
</ul>
<h2>Relationships</h2>
<p>ASSOCIATED_WITH_GENE::<a class="internal-link is-unresolved" href="/404">LPA Gene</a> - Determines &gt;90% of levels<br />
RISK_FACTOR_FOR::<a href="/garden/dev_admin/condition/cardiovascular-disease/" class="internal-link">Cardiovascular Disease</a> - Independent causal factor<br />
RISK_FACTOR_FOR::<a class="internal-link is-unresolved" href="/404">Aortic Valve Stenosis</a><br />
RISK_FACTOR_FOR::<a href="/garden/dev_admin/condition/myocardial-infarction/" class="internal-link">Myocardial Infarction</a><br />
SIMILAR_TO::<a href="/garden/dev_admin/biomarker/ldl/" class="internal-link">LDL</a> - Structural core<br />
INHIBITS::<a class="internal-link is-unresolved" href="/404">Plasminogen</a> - Pro-thrombotic mechanism<br />
AFFECTED_BY::<a class="internal-link is-unresolved" href="/404">PCSK9 Inhibitors</a> - Modest reduction<br />
UNAFFECTED_BY::<a class="internal-link is-unresolved" href="/404">Diet</a> - Generally resistant to lifestyle change<br />
UNAFFECTED_BY::<a class="internal-link is-unresolved" href="/404">Statins</a></p>
<h2>ðŸ’Š Supplements That Affect This Biomarker</h2>
<p>No supplement effects documented yet. Add effects in the respective supplement notes.</p>
<h2>ðŸ§ª Lab Tests That Measure This Biomarker</h2>
<p>No lab tests linked yet. Add biomarker measurements in the respective lab test notes.</p>
<h2>References</h2>
<ul>
<li>Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711.</li>
<li>Nordestgaard BG, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53.</li>
</ul>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<h3>Related</h3>
<ul>
<li>â†’ <a class="internal-link is-unresolved" href="/404">Lp_A</a> (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.579785'
source: obsidian
</code></pre>
<ul>
<li>â†’ <a href="/garden/dev_admin/biomarker/lp-a/" class="internal-link">Lp_A</a> (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:14.579785'
source: obsidian
</code></pre>
<!-- NEO4J_CONTENT_END -->
{% endraw %}